Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

MDS and MPN
21:56

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Leukemic Transformations of MPNs: What Mutations Are Associated With an Increased Risk? What Is the Efficacy of Standard Induction Therapy in Post-MPN AML? Does AlloSCT Offer Any Benefit?

FEATURING Tariq Mughal
  • 244 views
  • January 19, 2021
25:23

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

MDS Essentials: How Common Are Comorbidities? Should Risk Score Determine the Treatment Goal? What if the Patients Are Not Eligible for HSCT?

FEATURING Mustafa Çetiner
  • 70 views
  • January 18, 2021
09:57

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

LR-MDS: Are ESAs Effective in the Treatment of Anemia? Is PLT Transfusion Recommended for Thrombocytopenia?

FEATURING Moshe Mittelman
  • 15 views
  • January 18, 2021
10:25

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

HR-MDS: Are HMAs the Best Option? Should We Consider Changing the Paradigm?

FEATURING Moshe Mittelman
  • 109 views
  • January 18, 2021
  • 1
22:45

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Novel Approaches for PV: Can We Achieve CHR and Improve Disease Burden With Ropeginterferon Alfa-2b vs. SoC? Is 2L Ruxolitinib the Best Choice for HU-Resistant Patients?

FEATURING Martin Ellis
  • 5 views
  • January 18, 2021
12:47

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

MDS Updates: Can We Achieve Long-Term Transfusion Independence With Luspatercept? Is It Possible to Reach 5-Day AUC Equivalence With IV-Dec? Should We Use Ven+Aza Combo in Treatment-Naïve Patients?

FEATURING Guillermo Garcia-Manero
  • 304 views
  • January 11, 2021